DDDante Disharoon

Dante Disharoon

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Dante Disharoon has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A Stearyl‐Peptide Based Versatile Strategy to Design Enzyme‐Responsive Liposomes for Targeted Drug Delivery

    by Shruti Raghunathan, Norman Luc, Dante Disharoon, Sonali Rohiwal, Keren Hu, Rahul Darbhakul, Jenny Lian, Hanyang Wang, Rohini Sekar, Bipin Chakravarthy Paruchuri, et al.

    Liposomes are a prominent class of drug delivery nanoparticles. For currently approved liposomal therapeutics, drug is released predominantly via diffusion which has spatio‐temporal kinetic and bioavailability challenges, especially in a dynamic environment. Next‐generation liposome designs focus on stimuli‐triggered enhancement of drug release. One exciting approach here is liposomes that can be site‐specifically destabilized by disease‐associated enzymes. Feasibility of this has been demonstrated with certain phospholipases or metalloproteases, but a versatile strategy for designing liposomes triggerable by any disease‐specific enzyme remains lacking. We report a unique liposome design using enzyme‐cleavable stearyl‐peptide conjugates. Stearylamine has been explored for cationic liposomes in gene delivery, but the cationic charge poses significant cytotoxicity. We demonstrate that conjugating enzyme‐cleavable peptides to stearylamine and assembly of stearyl‐peptide conjugates within liposomes mitigates the cationic charge and significantly enhances biosafety. Surface‐decorating such liposomes with target‐specific ligands enables their active target‐anchorage under flow. Exposure of target‐anchored liposomes to disease‐relevant enzymes renders stearyl‐peptide cleavage and liposome destablization, enhancing drug release. We demonstrate the design versatility utilizing microfluidic models of three different vascular pathologies (hyperfibrinolysis, thrombosis and thromboinflammation) and delivering three corresponding drugs (tranexamic acid, tissue plasminogen activator and deoxyribonulease) triggered by three different enzymes (plasmin, thrombin and neutrophil elastase), respectively.

  • Open Access

    Species-specific, multifaceted venom resistance in Monodelphis domestica reveals novel physiological behavior of von Willebrand Factor under flow

    by Matthew Holding, Dante Disharoon, Laura Haynes, Bipin Chakravarthy Paruchuri, M. Hao Hao Pontius, Krista Golden, Jordan A. Shavit, Karl Desch, David Ginsburg, Anirban Sen Gupta, et al.

    Interactions between predators and prey are often characterized by strong selection pressures that shape extreme physiological adaptations. Venom resistance in large-bodied South American opossums (Clade Didelphini) is a striking example, as these marsupials prey on venomous snakes and exhibit remarkable resistance to their venom. While resistance is well documented in Didelphini, relatively little is known about venom resistance in the smaller, more diverse members of Didelphidae, which inhabit the same regions and encounter the same predators. Here, we investigate venom resistance in the small-bodied opossum, Monodelphis domestica , through multi-level physiological assays, examining responses to purified venom components and whole venom from sympatric and allopatric vipers. Our results show M. domestica resists venom-induced disruptions to blood coagulation, retains platelet function in the presence of platelet-disrupting venoms, and inhibits snake venom metalloproteinases. Unexpectedly, we find that M. domestica von Willebrand Factor (VWF) requires increased shear force to elongate, a previously unknown aspect of opossum blood physiology that may contribute to venom resistance and may have relevance to human coagulopathies. These findings expand the extent of venom resistance beyond large-bodied Didelphini, suggesting it is a widespread trait in South American marsupials and providing new insights into venom-mammal coevolution. Abstract Figure:

  • Open Access

    OC 15.5 Detection of TIC-Relevant Phenotypes using Bioactive Reagent-Functionalized Dielectric Coagulometry Microsensors

    by D. Disharoon, S. Pourang, C. Delianides, S. Ahuja, M. Suster, M. Neal, P. Mohseni, A. Sen Gupta

  • Open Access

    Magnetically Powered Microwheel Thrombolysis of Occlusive Thrombi in Zebrafish

    by M. Hao Hao Pontius, Chia-Jui Ku, Matthew J. Osmond, Dante Disharoon, Yang Liu, David W.M. Marr, Keith B. Neeves, Jordan A. Shavit

    Tissue plasminogen activator (tPA) is the only FDA approved treatment for ischemic stroke but carries significant risks, including major hemorrhage. Additional options are needed, especially in small vessel thrombi which account for ∼25% of ischemic strokes. We have previously shown that tPA-functionalized colloidal microparticles can be assembled into microwheels (µwheels) and manipulated under the control of applied magnetic fields to enable rapid thrombolysis of fibrin gels in microfluidic models of thrombosis. Providing a living microfluidic analog, transparent zebrafish larvae have a highly conserved coagulation cascade that enables studies of hemostasis and thrombosis in the context of intact vasculature, clotting factors, and blood cells. Here we show that tPA-functionalized µwheels can perform rapid and targeted recanalization in vivo . This effect requires both tPA and µwheels, as minimal to no recanalization is achieved with tPA alone, µwheels alone, or tPA-functionalized microparticles in the absence of a magnetic field. We evaluated tPA-µwheels in CRISPR-generated plasminogen ( plg ) heterozygous and homozygous mutants and confirmed that tPA-µwheels are dose-dependent on plasminogen for lysis. We have found that magnetically powered µwheels as a targeted tPA delivery system are dramatically more efficient at plasmin-mediated thrombolysis than systemic delivery in vivo . Further development of this system in fish and mammalian models could enable a less invasive strategy for alleviating ischemia that is safer than directed thrombectomy or systemic infusion of tPA.

  • Efficacy of platelet-inspired hemostatic nanoparticles on bleeding in Von Willebrand disease murine models

    by Stéphanie Roullet, Norman Luc, Julie Rayes, Jean Solarz, Dante Disharoon, Andrew J Ditto, Emily Gahagan, Christa Pawlowski, Thibaud Sefiane, Frédéric Adam, et al.

    The lack of innovation in Von Willebrand disease (VWD) originates from many factors including the complexity and heterogeneity of the disease but also from a lack of recognition of the impact of the bleeding symptoms experienced by VWD patients. Recently, a few research initiatives aiming to move past replacement therapies using plasma-derived or recombinant Von Willebrand factor (VWF) concentrates have started to emerge. Here we report an original approach using synthetic platelet (SP) nanoparticles for treatment of VWD type 2B (VWD-2B) and severe VWD (type 3 VWD). SP are liposomal nanoparticles decorated with peptides enabling them to concomitantly bind to collagen, VWF and activated platelets. In vitro, using various microfluidic assays, we show the efficacy of SP to improve thrombus formation in VWF-deficient condition (with human platelets) or using blood from VWD-2B mice and VWF-deficient mice (VWF-KO, i.e., type 3 VWD). In vivo, using a tail clip assay, SP treatment reduced blood loss by 35% in VWD-2B mice and 68% in VWF-KO mice. Additional studies using nanoparticles decorated with various combinations of peptides demonstrated that the collagen binding peptide, although not sufficient by itself, was absolutely crucial for SP efficacy in VWD-2B while all three peptides appeared necessary for VWF-KO mice. Clot imaging by immunofluorescence and scanning electron microscopy revealed that SP treatment of VWF-KO mice led to a strong clot, similar to those obtained in wild-type mice. Altogether, our results show that SP could represent an attractive therapeutic alternative for VWD, especially considering their long half-life and stability.


  • Assessment of fibrinolytic status in whole blood using a dielectric coagulometry microsensor

    by Sina Pourang, Ujjal D.S. Sekhon, Dante Disharoon, Sanjay P. Ahuja, Michael A. Suster, Anirban Sen Gupta, Pedram Mohseni


  • Breaking the fibrinolytic speed limit with microwheel co‐delivery of tissue plasminogen activator and plasminogen

    by Dante Disharoon, Brian G. Trewyn, Paco S. Herson, David W.M. Marr, Keith B. Neeves


  • An experimental design for the control and assembly of magnetic microwheels

    by E. J. Roth, C. J. Zimmermann, D. Disharoon, T. O. Tasci, D. W. M. Marr, K. B. Neeves

    Superparamagnetic colloidal particles can be reversibly assembled into wheel-like structures called microwheels (μwheels), which roll on surfaces due to friction and can be driven at user-controlled speeds and directions using rotating magnetic fields. Here, we describe the hardware and software to create and control the magnetic fields that assemble and direct μwheel motion and the optics to visualize them. Motivated by portability, adaptability, and low-cost, an extruded aluminum heat-dissipating frame incorporating open optics and audio speaker coils outfitted with high magnetic permeability cores was constructed. Open-source software was developed to define the magnitude, frequency, and orientation of the magnetic field, allowing for real-time joystick control of μwheels through two-dimensional (2D) and three-dimensional (3D) fluidic environments. With this combination of hardware and software, μwheels translate at speeds up to 50 µm/s through sample sizes up to 5 × 5 × 5 cm3 using 0.75 mT–2.5 mT magnetic fields with rotation frequencies of 5 Hz–40 Hz. Heat dissipation by aluminum coil clamps maintained sample temperatures within 3 °C of ambient temperature, a range conducive for biological applications. With this design, μwheels can be manipulated and imaged in 2D and 3D networks at length scales of micrometers to centimeters.